+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06274268

Evaluating Sarcopenia as a Predictor of Toxicity in First-Line Anti-Cancer Treatment A Prospective Diagnostic Study

Led by Centre Hospitalier Metropole Savoie · Updated on 2026-10-08

700

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating whether sarcopenia, a condition characterized by loss of muscle mass and strength, can predict the occurrence of toxicity during the initial phase of anti-cancer treatment in patients with various types of solid cancers. This prospective, interventional study is conducted at a single center and focuses on patients starting first-line systemic cancer therapy. The main goal is to understand if body composition and muscle performance impact treatment-related side effects. Participants will undergo specific assessments during their first chemotherapy session, including measurements of body composition using impedancemetry, grip strength tests, and chair rise tests. They will also receive actimeters to monitor physical activity. Subsequent data collections will occur during the second chemotherapy cycle, and at 6 and 12 months after treatment initiation, involving medical record reviews. An optional exploratory sub-study for breast cancer patients on the ACPACLITAXEL protocol includes additional visits and data collections focused on neuropathy and toxicity related to this treatment. Throughout the study, participants will be assessed using physical tests and questionnaires related to nutrition and physical activity. Researchers will monitor event-free survival from the first to the second treatment cycle and evaluate other outcomes such as progression-free survival, overall survival, and treatment response at 6 and 12 months. The study involves minimal extra procedures beyond usual care, and safety monitoring is integrated into routine clinical visits. The total study duration extends to 12 months of follow-up.

CONDITIONS

Brief Title

Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments

Research Team

A

Aurelie FILLON

N

Nathalie MARQUES, Dr

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here